Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.32 |
| ▸ | PYGB | P11216 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.30 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873358 | 0.78 | CA12 (0.32) | — | |
| SCHEMBL19502461 | 0.76 | HOGA1 (0.30) | — | |
| SCHEMBL8331534 | 0.73 | PYGB (0.44) | EPHX2PYGBLGALS3ALDH1A1 | |
| SCHEMBL14189087 | 0.73 | ADORA2A (0.41) | MEN1KMT2A | |
| SCHEMBL12110848 | 0.73 | ADORA3 (0.43) | SMN1; SMN2 | |
| SCHEMBL29300368 | 0.71 | IDUA (0.36) | EPHX2 | |
| SCHEMBL1432239 | 0.71 | ADORA2A (0.41) | MEN1KMT2A | |
| SCHEMBL16553551 | 0.71 | ADORA2A (0.41) | MEN1KMT2A | |
| SCHEMBL26292937 | 0.71 | HSP90AA1 (0.30) | — | |
| SCHEMBL14519956 | 0.70 | IDUA (0.33) | PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227504-A1 | Pegylated Factor VII Glycoforms | NOVO NORDISK A/S (DK) | 2009-09-10 | — | — | US | disclosed |
| US-20080039373-A1 | Pegylated Factor VII Glycoforms | NOVO NORDISK A/S (DK) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227504-A1 | Pegylated Factor VII Glycoforms | F7, F13B, F5 | MEN1 2340/4885KMT2A 4232/4885SMN1; SMN2 3205/4885 |
| US-20080039373-A1 | Pegylated Factor VII Glycoforms | F7, F13B, F5 | MEN1 2340/4885KMT2A 4232/4885SMN1; SMN2 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.